Beckman Coulter and Fujirebio expand partnership to develop patient-friendly, blood-based neurodegenerative disease diagnostics
The partnership focuses on development, manufacturing and clinical adoption of neurodegenerative disease assays
13 Mar 2024
Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, have announced an expansion of their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative disease assays.
In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer’s disease therapeutics. These new drugs are proving to be major milestones in slowing down disease progression and improving patients’ health. This recent announcement extends this research program and further refines target analytes, including a pTau217 plasma assay being developed by Beckman Coulter and a beta amyloid 1-42 plasma assay being developed by Fujirebio.
These new assays are being developed for use on the recently introduced Beckman Coulter DxI 9000 Immunoassay Analyzer. The DxI 9000 Analyzer’s Lumi-Phos PRO Substrate has shown the capability to develop increasingly sensitive and clinically relevant assays.
The agreement leverages Fujirebio’s expertise in the development, manufacturing and regulatory registration of its Neurological Reagent Kits and its expansive Neurological Biomarker menu. Fujirebio has developed a full complement of research use only (RUO) blood-based neurodegenerative biomarkers including β-amyloid1-42, β-amyloid1-40, phospho-Tau181, neurofilament light (NfL), ApoE4, Pan-ApoE and phospho-Tau217.